Sai Life Sciences IPO
Incorporation & Overview Sai Life Sciences Limited, incorporated in January 1999, specializes in research, development, and manufacturing of small-molecule new chemical entities. The company provides customized services to global biotech and pharmaceutical innovators. Business Overview
Clientele:
In FY 2024 and until September 30, 2024, the company served over 280 innovator pharmaceutical companies.
Notable collaborations with 18 of the top 25 global pharmaceutical companies (based on 2023 revenue).
Services offered across major markets including the US, UK, Europe, and Japan.
Service Offerings:
Chemistry, Manufacturing, and Control (CMC)/Contract Development and Manufacturing (CDMO).
Contract Research Organization (CRO) services, including integrated discovery capabilities in biology, chemistry, drug metabolism, and pharmacokinetics.
Promoter Shareholding
Promoters: Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Private Limited, Sunflower Partners, Lily Partners, Marigold Partners, and Tulip Partners.
Shareholding Pre-Issue: 40.48%
Shareholding Post-Issue: 35.1%
Objects of the Issue
Repayment of Borrowings: To reduce the company’s debt burden.
General Corporate Purposes: To support business growth and operational enhancements.
Sai Life Sciences IPO: Key Details
IPO Dates: 11 to 13 December, 2024
Price Band : ₹522 to ₹549 per share
Lot Size: 27 shares
Total Issue size: ₹3,042.62 Crores
Retail Quota: 35%
GMP: 5% (For Informational purposes only)
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.
Comments